Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Second mitochondria-derived activator of caspases (Smac) mimetics in combination with immunotherapy for treatment against aggressive neuroblastoma

FY 2016-17

Summary
Project title: Combination immunotherapy for aggressive neuroblastoma Background: Dr. Korneluk’s group discovered a family of oncogenes twenty years ago, called the inhibitors of apoptosis (IAPs). The IAPs control cell death, cell proliferation and importantly, they control innate and adaptive immunity. For the past decade the Korneluk group has been studying the mechanism of action of a class of drugs that antagonize the IAPs, known as Smac mimetic compounds (SMCs). In addition, the lab is investigating the roles in cancer and immunity played by the IAPs. SMCs represent a promising form of drug-based cancer immunotherapy. These compounds have been shown by the Korneluk lab and others to significantly increase the activity of various cancer immunotherapy approaches including immune checkpoint inhibitors. As well, SMC are currently in clinical trials for various diseases. Last year saw the approval in the US of dinutuximab (a GD2 glycolipid targeting antibody) for the treatment of advanced aggressive neuroblastoma. Neuroblastoma is the most common extracranial solid cancer in childhood, with up to two thirds of cases diagnosed after metastasis. This project intends to evaluate the use of SMCs with therapeutic antibodies that directly target cancer cells for the presence of synergistic effects. Hopefully this research will lead to improved cancer treatments in the future.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
373041
Name
Michalicka Matt
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Second mitochondria-derived activator of caspases (Smac) mimetics in combination with immunotherapy for treatment against aggressive neuroblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
In Vivo And In Vitro; Apoptosis; Cancer Treatment; Combination Immunotherapy; Gd2 Antibody; Immunostimulatory; Innate Immunity; Neuroblastoma; Pediatric Cancer; Smac Mimetic
Abstract
Project title: Combination immunotherapy for aggressive neuroblastoma Background: Dr. Korneluk’s group discovered a family of oncogenes twenty years ago, called the inhibitors of apoptosis (IAPs). The IAPs control cell death, cell proliferation and importantly, they control innate and adaptive immunity. For the past decade the Korneluk group has been studying the mechanism of action of a class of drugs that antagonize the IAPs, known as Smac mimetic compounds (SMCs). In addition, the lab is investigating the roles in cancer and immunity played by the IAPs. SMCs represent a promising form of drug-based cancer immunotherapy. These compounds have been shown by the Korneluk lab and others to significantly increase the activity of various cancer immunotherapy approaches including immune checkpoint inhibitors. As well, SMC are currently in clinical trials for various diseases. Last year saw the approval in the US of dinutuximab (a GD2 glycolipid targeting antibody) for the treatment of advanced aggressive neuroblastoma. Neuroblastoma is the most common extracranial solid cancer in childhood, with up to two thirds of cases diagnosed after metastasis. This project intends to evaluate the use of SMCs with therapeutic antibodies that directly target cancer cells for the presence of synergistic effects. Hopefully this research will lead to improved cancer treatments in the future.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Michalicka, Matt
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~